dc.contributor.author |
Elston, Marianne S |
|
dc.contributor.author |
Love, Amanda |
|
dc.contributor.author |
Kevat, Dev |
|
dc.contributor.author |
Carroll, Richard |
|
dc.contributor.author |
Siow, Zhen Rong |
|
dc.contributor.author |
Pattison, Sharon |
|
dc.contributor.author |
Boyle, Veronica |
|
dc.contributor.author |
Segelov, Eva |
|
dc.contributor.author |
Strickland, Andrew H |
|
dc.contributor.author |
Wyld, David |
|
dc.contributor.author |
Gauci, Richard |
|
dc.contributor.author |
Kennedy, Kim |
|
dc.contributor.author |
Ransom, David |
|
dc.contributor.author |
Commonwealth Neuroendocrine Tumour Collaboration (CommNETs) |
|
dc.coverage.spatial |
United States |
|
dc.date.accessioned |
2022-08-23T23:50:27Z |
|
dc.date.available |
2022-08-23T23:50:27Z |
|
dc.date.issued |
2021-12 |
|
dc.identifier.citation |
(2021). Cancer Medicine, 10(23), 8405-8411. |
|
dc.identifier.issn |
2045-7634 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/60931 |
|
dc.description.abstract |
Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors. Normal pituitary tissue expresses somatostatin receptors so patients receiving PRRT may be at risk of developing hypopituitarism. The aim was to assess the prevalence of clinically significant hypopituitarism a minimum of 2 years following radioisotope therapy for metastatic NET. This was a multicentre study (Australia and New Zealand). Sixty-six patients with unresectable NETs were included-34 had received PRRT and 32 comparison patients. Median follow-up after PRRT was 68 months. Male hypogonadism was the most common hormonal abnormality (16 of 38 men [42%]) from the total cohort. Of these, seven men had primary hypogonadism (five from PRRT group) and nine had secondary hypogonadism (six in PRRT group). There was no difference in either male hypogonadism or other hormonal dysfunction between patients who had received PRRT and those that had not. Patients who have received PRRT out to 68 months following treatment do not show concerning hypopituitarism although there may be the suggestion of growth hormone deficiency developing. However, hypogonadism is common in men with NETs so the gonadal axis should be assessed in men with suggestive symptoms as the treatment of testosterone deficiency may improve the quality of life. |
|
dc.format.medium |
Print-Electronic |
|
dc.language |
eng |
|
dc.publisher |
Wiley |
|
dc.relation.ispartofseries |
Cancer medicine |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.rights.uri |
https://creativecommons.org/licenses/by/4.0/ |
|
dc.subject |
Commonwealth Neuroendocrine Tumour Collaboration (CommNETs) |
|
dc.subject |
Humans |
|
dc.subject |
Neuroendocrine Tumors |
|
dc.subject |
Hypopituitarism |
|
dc.subject |
Receptors, Peptide |
|
dc.subject |
Pituitary Function Tests |
|
dc.subject |
Radiotherapy Dosage |
|
dc.subject |
Quality of Life |
|
dc.subject |
Aged |
|
dc.subject |
Middle Aged |
|
dc.subject |
Australia |
|
dc.subject |
New Zealand |
|
dc.subject |
Female |
|
dc.subject |
Male |
|
dc.subject |
hypogonadism |
|
dc.subject |
neuroendocrine tumours |
|
dc.subject |
radioisotopes |
|
dc.subject |
receptor |
|
dc.subject |
somatostatin |
|
dc.subject |
Rare Diseases |
|
dc.subject |
Clinical Research |
|
dc.subject |
Neurosciences |
|
dc.subject |
Science & Technology |
|
dc.subject |
Life Sciences & Biomedicine |
|
dc.subject |
Oncology |
|
dc.subject |
MESSENGER-RNA |
|
dc.subject |
EXPRESSION |
|
dc.subject |
LU-177-DOTATATE |
|
dc.subject |
ASSOCIATION |
|
dc.subject |
0601 Biochemistry and Cell Biology |
|
dc.subject |
1112 Oncology and Carcinogenesis |
|
dc.title |
Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1002/cam4.4345 |
|
pubs.issue |
23 |
|
pubs.begin-page |
8405 |
|
pubs.volume |
10 |
|
dc.date.updated |
2022-07-21T01:47:49Z |
|
dc.rights.holder |
Copyright: The authors |
en |
dc.identifier.pmid |
34697905 (pubmed) |
|
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/34697905 |
|
pubs.end-page |
8411 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
research-article |
|
pubs.subtype |
Multicenter Study |
|
pubs.subtype |
Journal Article |
|
pubs.elements-id |
871378 |
|
pubs.org-id |
Medical and Health Sciences |
|
pubs.org-id |
School of Medicine |
|
pubs.org-id |
Medicine Department |
|
dc.identifier.eissn |
2045-7634 |
|
pubs.record-created-at-source-date |
2022-07-21 |
|
pubs.online-publication-date |
2021-12 |
|